GlaxoSmithKline (LON:GSK) received a GBX 2,000 ($26.13) price target from investment analysts at HSBC in a research report issued to clients and investors on Thursday. The brokerage currently has a “buy” rating on the stock. HSBC’s target price suggests a potential upside of 35.14% from the company’s current price.
GSK has been the subject of several other reports. Credit Suisse Group set a GBX 1,450 ($18.95) target price on GlaxoSmithKline and gave the company a “neutral” rating in a research note on Monday, July 16th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, October 23rd. UBS Group reaffirmed a “buy” rating and set a GBX 1,700 ($22.21) price objective (up from GBX 1,600 ($20.91)) on shares of GlaxoSmithKline in a research note on Monday, July 30th. Deutsche Bank reaffirmed a “hold” rating and set a GBX 1,525 ($19.93) price objective on shares of GlaxoSmithKline in a research note on Thursday, September 6th. Finally, Kepler Capital Markets set a GBX 1,440 ($18.82) price objective on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Monday, July 30th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. GlaxoSmithKline currently has a consensus rating of “Hold” and a consensus target price of GBX 1,521.27 ($19.88).
LON GSK opened at GBX 1,480 ($19.34) on Thursday. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($16.14) and a 52 week high of GBX 1,724.50 ($22.53).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: Marijuana Stocks
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.